Scientists hunt blood clues in fight against deadly brain cancer
NCT ID NCT04817254
Summary
This study is testing whether adding immune-boosting drugs (nivolumab and ipilimumab) to standard chemotherapy can help people with newly diagnosed glioblastoma, a very aggressive brain cancer. Researchers will track 47 adults who have already had surgery and initial treatment, looking closely at changes in their blood immune cells during therapy. The main goal is to see if these blood changes predict whether patients live longer, which could help identify who benefits most from this type of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.